Published: 26 Aug 2020 | Report Code: 10247663 | Pages: 145
Europe digital biomarkers market accounted for $118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic. Highlighted with 42 tables and 67 figures, this 145-page report “Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country. Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Data Collection Tools • Digital Platforms • Mobile Apps • Desktop-based Software • Wearables • Biosensors Data Integration Systems Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cardiovascular Diseases Neurodegenerative Disorders • Parkinson’s Disease • Multiple Sclerosis • Alzheimer’s Disease Sleep and Movement Diseases Psychiatric Disorders Chronic Pain Gastrointestinal Diseases Diabetes Respiratory Conditions Other Diseases Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Wellness • Disease Diagnosis • Personalised Medication • Drug Discovery and Development Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Novel Digital Biomarkers • Original Digital Biomarkers • Approved Digital Biomarkers Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Biopharmaceutical Companies & Labs • Healthcare Providers • Insurance Payers Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Netherlands • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table Of Contents
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 14 1.2.6 Market Size/Share Estimation 15 1.2.7 Research Limitations 16 1.3 Executive Summary 17 2 Market Overview and Dynamics 20 2.1 Market Size and Forecast 20 2.1.1 Impact of COVID-19 on the Market 25 2.2 Major Growth Drivers 27 2.3 Market Restraints and Challenges 32 2.4 Emerging Opportunities and Market Trends 37 2.5 Porter’s Fiver Forces Analysis 41 3 Segmentation of Europe Market by System Component 45 3.1 Market Overview by System Component 45 3.2 Data Collection Tools 47 3.2.1 Digital Platforms 49 3.2.2 Mobile Apps 50 3.2.3 Desktop-based Software 51 3.2.4 Wearables 52 3.2.5 Biosensors 53 3.3 Data Integration Systems 54 4 Segmentation of Europe Market by Therapeutic Area 55 4.1 Market Overview by Therapeutic Area 55 4.2 Cardiovascular Diseases 57 4.3 Neurodegenerative Disorders 58 4.3.1 Parkinson’s Disease 60 4.3.2 Multiple Sclerosis 61 4.3.3 Alzheimer’s Disease 62 4.4 Sleep and Movement Diseases 63 4.5 Psychiatric Disorders 64 4.6 Chronic Pain 65 4.7 Gastrointestinal Diseases 66 4.8 Diabetes 67 4.9 Respiratory Conditions 68 4.10 Other Diseases 69 5 Segmentation of Europe Market by Application 70 5.1 Market Overview by Application 70 5.2 Wellness 72 5.3 Disease Diagnosis 73 5.4 Personalised Medication 74 5.5 Drug Discovery and Development 75 6 Segmentation of Europe Market by Development Status 77 6.1 Market Overview by Development Status 77 6.2 Novel Digital Biomarkers 80 6.3 Original Digital Biomarkers 81 6.4 Approved Digital Biomarkers 82 7 Segmentation of Europe Market by End User 83 7.1 Market Overview by End User 83 7.2 Biopharmaceutical Companies & Labs 85 7.3 Healthcare Providers 86 7.4 Insurance Payers 87 8 European Market 2019-2030 by Country 88 8.1 Overview of European Market 88 8.2 Germany 91 8.3 UK 93 8.4 France 95 8.5 Netherlands 97 8.6 Italy 99 8.7 Russia 101 8.8 Rest of European Market 103 9 Competitive Landscape 105 9.1 Overview of Key Vendors 105 9.2 New Product Launch, Partnership, Investment, and M&A 109 9.3 Company Profiles 110 Actigraph LLC 110 Akili Interactive Labs 112 AliveCor Inc 113 Altoida Inc 114 Amgen Inc 115 Bayer AG 116 Biogen Inc 117 Cambridge Cognition Plc 118 Eli Lilly and Company 119 Evidation Health, Inc. 120 F. Hoffmann-La Roche Ltd 121 Fitbit Inc 122 GlaxoSmithKline Plc 123 Happify Health 124 Human API 125 IXICO Plc 126 Koninklijke Philips N.V. 127 Medical Care Corporation 128 Medopad Ltd 129 Mindstrong Health 130 Neurotrack Technology, Inc 131 Novartis International AG 132 Pfizer Inc. 133 Quanterix Corporation 134 Sanofi S.A. 135 The Takeda Pharmaceuticals Company Limited 136 Verily Life Sciences 137 Winterlight Labs Inc. 138 10 Investing in Europe Market: Risk Assessment and Management 139 10.1 Risk Evaluation of Europe Market 139 10.2 Critical Success Factors (CSFs) 142 Related Reports and Products 145
List Of Tables
Table 1. Snapshot of Europe Digital Biomarkers Market, 2019-2030 18 Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22 Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30 Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31 Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31 Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34 Table 7. Main Product Trends and Market Opportunities in Europe Digital Biomarkers Market 37 Table 8. Europe Digital Biomarkers Market by System Component, 2019-2030, $ mn 45 Table 9. Europe Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 48 Table 10. Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 55 Table 11. Europe Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 59 Table 12. Europe Digital Biomarkers Market by Application, 2019-2030, $ mn 70 Table 13. Europe Digital Biomarkers Market by Development Status, 2019-2030, $ mn 78 Table 14. Europe Digital Biomarkers Market by End User, 2019-2030, $ mn 83 Table 15. Europe Digital Biomarkers Market by Country, 2019-2030, $ mn 90 Table 16. Germany Digital Biomarkers Market by System Component, 2019-2030, $ mn 92 Table 17. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 92 Table 18. Germany Digital Biomarkers Market by End User, 2019-2030, $ mn 92 Table 19. UK Digital Biomarkers Market by System Component, 2019-2030, $ mn 94 Table 20. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 94 Table 21. UK Digital Biomarkers Market by End User, 2019-2030, $ mn 94 Table 22. France Digital Biomarkers Market by System Component, 2019-2030, $ mn 96 Table 23. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 96 Table 24. France Digital Biomarkers Market by End User, 2019-2030, $ mn 96 Table 25. Netherlands Digital Biomarkers Market by System Component, 2019-2030, $ mn 98 Table 26. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 98 Table 27. Netherlands Digital Biomarkers Market by End User, 2019-2030, $ mn 98 Table 28. Italy Digital Biomarkers Market by System Component, 2019-2030, $ mn 100 Table 29. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 100 Table 30. Italy Digital Biomarkers Market by End User, 2019-2030, $ mn 100 Table 31. Russia Digital Biomarkers Market by System Component, 2019-2030, $ mn 102 Table 32. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 102 Table 33. Russia Digital Biomarkers Market by End User, 2019-2030, $ mn 102 Table 34. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, $ mn 104 Table 35. Breakdown of Europe Market by Key Vendor, 2019, % 107 Table 36. Actigraph LLC: Company Snapshot 110 Table 37. Actigraph LLC: Business Segmentation 110 Table 38. Actigraph LLC: Product Portfolio 111 Table 39. Actigraph LLC: Revenue, 2016-2018, $ mn 111 Table 40. Actigraph LLC: Recent Developments 111 Table 41. Risk Evaluation for Investing in Europe Market, 2019-2030 140 Table 42. Critical Success Factors and Key Takeaways 143
List Of Figures
Figure 1. Research Method Flow Chart 11 Figure 2. Breakdown of Primary Research 13 Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15 Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17 Figure 5. Europe Digital Biomarkers Market, 2019-2030, $ mn 20 Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers 21 Figure 7. Benefits and Challenges of Digital Biomarkers 23 Figure 8. Europe Biomarkers Market, 2019-2030, $ mn 24 Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030 24 Figure 10. Impact of COVID-19 on Business 25 Figure 11. Primary Drivers and Impact Factors of Europe Digital Biomarkers Market 27 Figure 12. World 5G Traffic, 2019-2030, EB/year 30 Figure 13. Primary Restraints and Impact Factors of Europe Digital Biomarkers Market 32 Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers 35 Figure 15. Pathway to Regulatory Approval of Digital Biomarkers 36 Figure 16. Investment Opportunity Analysis 38 Figure 17. Porter’s Fiver Forces Analysis of Europe Digital Biomarkers Market 41 Figure 18. Breakdown of Europe Digital Biomarkers Market by System Component, 2019-2030, % of Revenue 46 Figure 19. Europe Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%) 46 Figure 20. Europe Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn 47 Figure 21. Europe Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn 49 Figure 22. Europe Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn 50 Figure 23. Europe Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn 51 Figure 24. Europe Digital Biomarkers Market: Wearables, 2019-2030, $ mn 52 Figure 25. Europe Digital Biomarkers Market: Biosensors, 2019-2030, $ mn 53 Figure 26. Europe Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn 54 Figure 27. Breakdown of Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue 56 Figure 28. Europe Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%) 56 Figure 29. Europe Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn 57 Figure 30. Europe Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn 58 Figure 31. Europe Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn 60 Figure 32. Europe Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn 61 Figure 33. Europe Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn 62 Figure 34. Europe Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn 63 Figure 35. Europe Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn 64 Figure 36. Europe Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn 65 Figure 37. Europe Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn 66 Figure 38. Europe Digital Biomarkers Market: Diabetes, 2019-2030, $ mn 67 Figure 39. Europe Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn 68 Figure 40. Europe Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn 69 Figure 41. Breakdown of Europe Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue 71 Figure 42. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 71 Figure 43. Europe Digital Biomarkers Market: Wellness, 2019-2030, $ mn 72 Figure 44. Europe Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn 73 Figure 45. Europe Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn 74 Figure 46. Europe Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn 75 Figure 47. Classification of Digital Biomarkers by Development Status 77 Figure 48. Breakdown of Europe Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue 79 Figure 49. Europe Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%) 79 Figure 50. Europe Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn 80 Figure 51. Europe Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn 81 Figure 52. Europe Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn 82 Figure 53. Breakdown of Europe Digital Biomarkers Market by End User, 2019-2030, % of Revenue 84 Figure 54. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 84 Figure 55. Europe Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn 85 Figure 56. Europe Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn 86 Figure 57. Europe Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn 87 Figure 58. Breakdown of European Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue 89 Figure 59. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 90 Figure 60. Digital Biomarkers Market in Germany, 2019-2030, $ mn 91 Figure 61. Digital Biomarkers Market in UK, 2019-2030, $ mn 93 Figure 62. Digital Biomarkers Market in France, 2019-2030, $ mn 95 Figure 63. Digital Biomarkers Market in Netherlands, 2019-2030, $ mn 97 Figure 64. Digital Biomarkers Market in Italy, 2019-2030, $ mn 99 Figure 65. Digital Biomarkers Market in Russia, 2019-2030, $ mn 101 Figure 66. Digital Biomarkers Market in Rest of Europe, 2019-2030, $ mn 103 Figure 67. Growth Stage of Europe Digital Biomarkers Industry over the Forecast Period 105
Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc.